Stimulant Use Disorder Pocket Guide for Patients
Developed by AAAP and ASAM, this guideline focuses on the identification, diagnosis, treatment, and promotion of recovery for patients with stimulant use disorder, stimulant intoxication, and stimulant withdrawal.
Management of Stimulant Use Disorder Guideline
Developed by AAAP and ASAM, this guideline focuses on the identification, diagnosis, treatment, and promotion of recovery for patients with stimulant use disorder, stimulant intoxication, and stimulant withdrawal.
Opioid Use Disorder in Pregnant and Postpartum People: The Treatment and Policy Landscape
Opioid use disorder (OUD) can be a fatal addiction with complex implications for new and/or expecting mothers. OUD challenges can lead to many complications for mother and child, including low birth weight, clinical challenges with medical dosing and increased risk of accidental death. In the U.S. alone, a baby is born passively dependent every 15 minutes. To ensure best health outcomes for both mother and child, policies must allow engagement in evidence-based treatment and protect clients from legal ramifications. Hear from a physician, clinic director and an individual with lived experience to broaden understandings about the treatment and policy landscape for pregnant and postpartum women with OUD.
12: Lab Testing in Assessment of Substance Use Disorders
Lab testing in the assessment of substance use disorders may involve many different substrates, though urine drug testing (UDT) dominates clinical practice. This module is meant to provide a short guide to effective use of lab testing in treatment of the patient with a substance use disorder, which to a surprising degree is often misused or misunderstood. The module describes the clinical role of lab testing to guide treatment and not to be punitive. To properly use and interpret UDT, it reviews common false positive and false negatives that might occur in the immunologic-based first step in UDT. To understand confirmatory gas chromatography/mass spectrometry, it goes on to describe the metabolism of common opioids and benzodiazepines, because the detected confirmed moiety often is just a downstream metabolite of several possible parent compounds to which the patient was exposed. The module concludes with a discussion of the difference between UDT for clinical purposes versus forensic ones.
17: Nicotine and Stimulant Use in Adolescents
This module reviews recent trends in nicotine and stimulant use in adolescents in young adults. It also presents a summary of the neurobiology of nicotine, discusses the different health effects and risks of harm of nicotine and stimulants (including illicit stimulants, prescription stimulants and caffeine) and offers an overview of prevention and treatment strategies for youth.
20: Treating Pregnant People for Opioid Use Disorder: Clinical Challenges
Opioid use disorder (OUD) among women and people who become pregnant is increasing in prevalence in clinical settings. The standard of care is to provide buprenorphine or methadone as a part of a complete treatment approach during pregnancy and beyond the postpartum period. This module reviews the historical and current context of opioid use among women and birthing people during pregnancy. It compares pharmacological treatment options for women and people who become pregnant with an OUD and also discusses the issues with detoxification or medically assisted withdrawal from opioids during pregnancy. Issues related to the treatment of OUD during pregnancy and in the postpartum period for the birthing person, fetus and child will also be discussed (e.g., induction, dosing, pain management, neonatal withdrawal and how to reduce its severity).
22: Preventing Opioid-Involved Overdose with Education and Naloxone
Overdose is the leading cause of accidental injury death in the United States surpassing motor vehicle crashes, claiming more than 100,000 American lives annually. Fentanyl, a synthetic opioid, that is sold as heroin and counterfeit prescription opioids is driving the recent surges in overdose deaths in most communities. Overdose prevention, that includes equipping people who use drugs and their social networks with naloxone rescue kits is an established strategy to address opioid overdose.
